TREA

97730294 - NYXROSI

Follow

Information

  • Trademark
  • 97730294
  • Serial Number
    97730294
  • Filing Date
    December 23, 2022
    a year ago
  • Transaction Date
    April 09, 2024
    2 months ago
  • Status Date
    April 09, 2024
    2 months ago
  • Published for Opposition Date
    February 13, 2024
    4 months ago
  • Location Date
    April 09, 2024
    2 months ago
  • Status Code
    688
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    KOPENSKI, CLAUDIA ANN
  • Attorney Docket Number
    00161761-US
    Attorney Name
    Marilyn F. Kelly
    Law Office Assigned Location Code
    O20
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
NYXROSI
Case File Statements
  • GS0051: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Case File Event Statements
  • 4/9/2024 - 2 months ago
    14 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 2/13/2024 - 4 months ago
    13 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/13/2024 - 4 months ago
    12 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/24/2024 - 5 months ago
    11 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/8/2024 - 5 months ago
    10 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 12/15/2023 - 6 months ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/14/2023 - 6 months ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/14/2023 - 6 months ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 9/27/2023 - 9 months ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 9/27/2023 - 9 months ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 9/27/2023 - 9 months ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/23/2023 - 9 months ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 12/29/2022 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 12/27/2022 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP